

## **Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer**

**H. S. Hochster · N. Uboha · W. Messersmith ·  
P. J. Gold · B. H. O'Neil · D. Cohen · C. Denlinger ·  
S. Cohen · C. G. Leichman · L. Leichman · H.-J. Lenz**

Published online: 2 December 2014  
© Springer-Verlag Berlin Heidelberg 2014

**Erratum to: Cancer Chemother Pharmacol  
DOI 10.1007/s00280-014-2609-3**

Unfortunately, a co-author's name was not listed in the original publication. The missing author's name is given below:

H.-J. Lenz,  
University of Southern California, Los Angeles, CA, USA

---

The online version of the original article can be found under  
doi:[10.1007/s00280-014-2609-3](https://doi.org/10.1007/s00280-014-2609-3).

---

H. S. Hochster (✉) · N. Uboha  
Yale Cancer Center, 333 Cedar Street, New Haven,  
CT 06520, USA  
e-mail: [howard.hochster@yale.edu](mailto:howard.hochster@yale.edu)

W. Messersmith  
University of Colorado, Aurora, CO, USA

P. J. Gold  
Swedish Cancer Institute, Seattle, WA, USA

B. H. O'Neil  
Indiana University, Indianapolis, IN, USA

D. Cohen · C. G. Leichman · L. Leichman  
NYU Cancer Institute, New York, NY, USA

C. Denlinger · S. Cohen  
Fox Chase Cancer Center, Philadelphia, PA, USA

H.-J. Lenz  
University of Southern California, Los Angeles, CA, USA